Indications
Patients with type 2 diabetes mellitus (T2DM):
- GLIPTAMET is indicated as adjunctive therapy with diet and exercise in patients in whom metformin hydrochloride or vildagliptin monotherapy has not achieved adequate glycaemic control, or in patients already receiving treatment with a free combination of metformin hydrochloride and vildagliptin.
- GLIPTAMET is indicated in combination with a sulfonylurea (i.e., triple combination) as adjunctive therapy with diet and exercise in patients in whom treatment with metformin and a sulfonylurea alone does not achieve adequate glycaemic control.
- GLIPTAMET is indicated in combination with insulin to improve glycaemic control in patients in whom diet, exercise, and treatment with a stable dose of insulin and metformin do not achieve adequate glycaemic control.
API
Vildagliptin
Therapeutic area
Digestive system and metabolism + Metabolism and Nutrition
Forms
Coated tablets
Dosage
50 mg/850 mg
Presentation
B/60
Table
A